David Oxley

Commander
DISC Type : D

CEO, Vaccinogen | OncoVAX®— Immunotherapy to Prevent Stage II Colon Cancer Recurrence at Vaccinogen

United States

Overview

David Oxley is the CEO of Vaccinogen, spearheading the global strategy for OncoVAX®, a personalized immunotherapy for Stage II colon cancer. An alumnus of Johns Hopkins University with over 25 years in biotechnology and life sciences, his expertise spans capital markets, cross-border licensing, and navigating FDA regulatory pathways for novel therapies.

He holds Series 7 and 63 securities licenses, an uncommon qualification for a biotech CEO that highlights his distinct expertise in corporate finance and investor relations.

Personality Overview

Strong-Willed

Decisive

Risk-Taker

They like to stay in control of the negotiation or defining of the terms.  They prefer to move quickly, and expect the same from others. They put a lot of effort into ensuring personal success.

Topics They Care About

Cancer Immunotherapy
He is leading the development of OncoVAX® to prevent Stage II colon cancer recurrence, focusing on the post-surgical curative window to train the immune system.
Biotech Capital Markets
His background includes Series 7/63 licenses and experience with pre-IPO financing and readiness for NASDAQ/NYSE listings, demonstrating deep knowledge of biotech fundraising.
FDA Regulatory Pathways
Frequently advocates for his company's pivotal trial by highlighting its FDA Special Protocol Assessment (SPA) and Fast Track designation, showing his focus on regulatory strategy.

Media Appearances

Vaccinogen Lands $80M. Featured in VC News Daily

See Now

Work History

11-2025
CEO, Vaccinogen | OncoVAX®— Immunotherapy to Prevent Stage II Colon Cancer Recurrence at Vaccinogen
6-2025
Member Board of Directors at Caladrix
2-2023 - 11-2025
Chief Business Officer at BIORCHESTRA Co., Ltd.
8-2021 - 1-2023
President International at Exopharm Ltd
8-2017 - 9-2022
Sr. Vice President, Business Development & Licensing at Mesoblast Limited

Education

1996 - 1998
MA from The Johns Hopkins University

More Information

Social Presence :

Prographics :

Exp : 8 Location : United States Job Level : Leadership Designation : CEO, Vaccinogen | OncoVAX®— Immunotherapy to Prevent Stage II Colon Cancer Recurrence at Vaccinogen
URL has been copied!

Insights For Selling To David

During A Call Or A Meeting

DO's

  • Make sure that you circle back fast on any action items, it wins their trust
  • Be respectful but crisp
  • Refer to testimonials from well-known industry leaders

DONT's

  • Don’t be in a rush to invite them for a social meet and greet
  • Avoid being too verbose
  • Do not back off when challenged, respond with a confident, objective answer instead

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with David is

  • Conviction around the impact matters the most to them, followed by a sense of achievement and ROI.
  • Will you ever get a clear answer from David

  • If they decide not to use your product, they will say no clearly.

Insights For Deal Planning

    How fast (or slow) will David move?

  • If convinced, they can reach decisions quite fast.
  • Can David take some risk or not?

  • They do not shy away from taking risks, but can be quite binary about them.

You And David

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.